Table 2.
Patient characters and tumor-specific factors of the study population
| Characteristics | With VTE N = 312 |
Without VTE N = 248 |
P |
|---|---|---|---|
| Patient data | |||
| Age, y, IQR | 66.0 (60.0–73.0) | 64.0 (57.0–70.8) | 0.001 |
| ≥ 65 years, N (%) | 190 (60.9) | 114 (46.0) | < 0.001 |
| Male, N (%) | 199 (63.8) | 166 (66.9) | 0.437 |
| BMI, ± SD (kg/m2) | 24.2 ± 3.8 | 23.6 ± 4.0 | 0.077 |
| ≥ 25 (kg/m2), N (%) | 119 (38.1) | 82 (33.1) | 0.214 |
| Smoking history, N (%) | 119 (38.1) | 105 (42.3) | 0.314 |
| Past alcohol use, N (%) | 79 (25.3) | 64 (25.8) | 0.896 |
| Comorbidities, N (%) | |||
| Diabetes | 57 (18.3) | 55 (22.2) | 0.251 |
| Hypertension | 135 (43.3) | 98 (39.5) | 0.371 |
| Prior VTE | 56 (17.9) | 3 (1.2) | < 0.001 |
| MACCE | 55 (17.6) | 51 (20.6) | 0.378 |
| Causes of ICU admission | 0.002 | ||
| Surgical, N (%) | 205 (65.7) | 192 (77.4) | |
| Medical, N (%) | 107 (34.3) | 56 (22.6) | |
| Tumor category, N (%) | 0.244 | ||
| Lung cancer | 17 (5.4) | 16 (6.5) | |
| Hepatobiliary and pancreatic tumors | 28 (9.0) | 15 (6.0) | |
| Tumors of digestive system | 199 (63.8) | 167 (67.3) | |
| Breast cancer | 15 (4.8) | 3 (1.2) | |
| Gynecological tumors | 11 (3.5) | 10 (4.0) | |
| Retroperitoneal masses | 21 (6.7) | 19 (7.7) | |
| Others* | 21 (6.7) | 18 (7.3) | |
| Stagea | 0.513 | ||
| 1–3, N (%) | 216 (71.1) | 165 (68.5) | |
| 4, N (%) | 88 (28.9) | 76 (31.5) | |
| Gradea | 0.002 | ||
| 1–2, N (%) | 160 (52.6) | 158 (65.6) | |
| 3–4, N (%) | 144 (47.4) | 83 (34.4) | |
| Baseline test results | |||
| WBC, ×109/L, IQR | 5.9 (4.6–7.3) | 5.7 (4.6–7.6) | 0.755 |
| Hemoglobin, g/L, IQR | 124.0 (103.3–141.0) | 123.5 (101.0–141.8) | 0.984 |
| Platelet, ×109/L, IQR | 198.0 (153.3–266.8) | 181.5 (137.5–251.0) | 0.044 |
| Creatinine, μmol/L, IQR | 64.0 (53.0–74.0) | 67.0 (55.0–81.0) | 0.742 |
| Albumin, g/L, IQR | 41.4 (37.9–44.7) | 41.9 (37.4–44.8) | 0.479 |
| Bilirubin, μmol/L, IQR | 12.6 (9.1–17.6) | 12.1 (8.4–16.7) | 0.120 |
| Glucose, mmol/L, IQR | 5.7 (5.1–6.9) | 5.6 (5.0–6.8) | 0.985 |
| TC, mmol/L, IQRb | 4.37 (3.81–5.17) | 4.26 (3.52–4.98) | 0.039 |
| TG, mmol/L, IQRb | 1.18 (0.85–1.74) | 1.24 (0.85–1.85) | 0.299 |
| ABO blood group, N (%)c | 0.216 | ||
| A | 86 (27.8) | 85 (34.4) | |
| B | 100 (32.4) | 66 (26.7) | |
| AB | 32 (10.4) | 31 (12.6) | |
| O | 91 (29.4) | 65 (26.3) | |
| APTT, s, IQR | 30.1 (27.6–34.0) | 31.0 (28.5–35.3) | 0.362 |
| INR, IQR | 1.02 (0.97–1.08) | 1.04 (0.98–1.14) | 0.131 |
| D-dimer, μmol/L, IQRd | 1.18 (0.75–2.51) | 1.03 (0.67–2.12) | 0.052 |
| APECHE II | 10 (7–13) | 9 (7–12) | 0.145 |
*Other tumor types included the following: thyroid cancer, prostatic cancer, malignant melanoma, lymphoma, and benign tumor. aBenign lesion was occurred in 15 patients. bBaseline TC and TG examination were not available for 19 individuals. cABO blood group was not available for 4 individuals. dOne-hundred seventy-five patients did not receive D-dimer examination at admission. Data are n (% of total available data within each column), mean ± SD, or median (IQR)